5-Fluorouracil, heptaplatin and UFT combination chemotherapy for advanced or recurrent gastric cancer.
- Author:
Jung Hye KWON
1
;
Eun Kyung PARK
;
Jung Hee LEE
;
Sang Jae LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea. dazzlingston@chol.com
- Publication Type:Original Article
- Keywords:
Gastric cancer;
Heptaplatin;
Fluorouracil
- MeSH:
Drug Therapy, Combination*;
Fluorouracil*;
Humans;
Sepsis;
Stomach Neoplasms*
- From:Korean Journal of Medicine
2004;67(3):274-281
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study was performed in patients with advanced or recurrent gastric cancer to evaluate the efficacy and feasibility of combination chemotherapy with 5-fluorouracil, heptaplatin, and UFT. METHODS: Total 20 patients with advanced or recurrent gastric cancer were enrolled from April 1, 2000 to December 31, 2001 and analyzed for response, toxicity, and survival. The regimen consisted of heptaplatin 400 mg/m2 (day 1), 5-flurouracil 1,000 mg/m2/day (day 1 to 5, continuous infusion) and 5-FU 225 mg/m2/day (day 6 to 12, continuous infusion) or UFT 400 mg/d (day 6 to 22). The treatment was repeated by 28 days. RESULTS: 17 patients could be evaluated. The overall response rate was 47.1% (2 complete responses and 6 partial responses), and the median duration of response was 6.2 months (95% CI: range, 1.0~12.4 months). Median survival of the 20 patients was 11.7 months (95% CI: range, 4.2~19.8 months). Grade 4 hematologic toxicity with sepsis occurred in 1 cycle. CONCLUSION: Based on these results, this combination chemotherapy seems to be useful for advanced or recurrent gastric cancer.
